Wave Life Sciences (NASDAQ:WVE) issued its earnings results on Friday. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.26) by ($0.02), MarketWatch Earnings reports. Wave Life Sciences had a negative return on equity of 91.88% and a negative net margin of 1,473.26%. The business had revenue of $4.49 million for the quarter, compared to analysts’ expectations of $5.36 million.

WVE traded down $2.07 on Friday, reaching $43.16. The stock had a trading volume of 56,859 shares, compared to its average volume of 77,911. Wave Life Sciences has a 12-month low of $21.85 and a 12-month high of $56.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.11 and a current ratio of 6.11. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -11.21 and a beta of 1.10.

In other news, insider Chris Francis sold 11,575 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total transaction of $648,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Chandra Vargeese sold 3,000 shares of the business’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $55.00, for a total transaction of $165,000.00. The disclosure for this sale can be found here. Insiders sold 44,075 shares of company stock valued at $2,435,700 in the last ninety days. 44.20% of the stock is owned by corporate insiders.

A number of research analysts have weighed in on the stock. BidaskClub cut shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. Stifel Nicolaus assumed coverage on shares of Wave Life Sciences in a report on Monday, August 6th. They issued a “buy” rating and a $56.00 price objective for the company. Mizuho set a $65.00 price objective on shares of Wave Life Sciences and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Wave Life Sciences in a report on Monday, July 23rd. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Wave Life Sciences presently has a consensus rating of “Buy” and an average target price of $58.40.

WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://theolympiareport.com/2018/11/10/wave-life-sciences-wve-posts-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Article: Buyback For Investors Defined

Earnings History for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.